Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18821737 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18821730 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18821707 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18821718 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18654735 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | May 2024 | April 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18654902 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | May 2024 | April 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18511818 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | November 2023 | September 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18559201 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENS | November 2023 | August 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18494007 | HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | October 2023 | December 2024 | Allow | 13 | 2 | 0 | No | No |
| 18479317 | IMMUNOCONJUGATES AND METHODS | October 2023 | August 2024 | Allow | 11 | 2 | 0 | No | No |
| 18349337 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | July 2023 | September 2024 | Allow | 14 | 2 | 1 | No | No |
| 18254882 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | May 2023 | October 2024 | Allow | 17 | 3 | 0 | No | No |
| 18318384 | COVALENTLY-MODIFIED STEROID ACID-PEPTIDES HAVING ENHANCED STABILITY AND/OR BIOLOGICAL ACTIVITY | May 2023 | October 2024 | Allow | 17 | 1 | 0 | No | No |
| 18169174 | DENDRITIC CELL TUMOR VACCINE AND USES THEREOF | February 2023 | June 2024 | Allow | 16 | 4 | 0 | Yes | No |
| 18101285 | GLYCOME FACTORS DRIVING MELANOMA PROGRESSION | January 2023 | November 2023 | Allow | 9 | 2 | 0 | No | No |
| 18062996 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | December 2022 | January 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18056080 | ANTI-PSMA CONJUGATES | November 2022 | May 2024 | Abandon | 17 | 2 | 0 | No | No |
| 17936346 | IMMUNOCONJUGATES AND METHODS | September 2022 | August 2023 | Allow | 11 | 2 | 0 | No | No |
| 17823494 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | August 2022 | July 2023 | Allow | 10 | 1 | 0 | No | No |
| 17823492 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | August 2022 | September 2023 | Allow | 13 | 2 | 0 | Yes | No |
| 17851340 | IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF | June 2022 | August 2024 | Allow | 26 | 5 | 0 | No | No |
| 17836684 | PDGF MUTANTS AND METHODS OF USE THEREOF | June 2022 | February 2025 | Allow | 33 | 4 | 0 | No | No |
| 17831085 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | June 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17663758 | COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17736896 | Methods for Manipulating Phagocytosis Mediated by CD47 | May 2022 | July 2023 | Abandon | 15 | 2 | 0 | No | No |
| 17754915 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | April 2022 | April 2025 | Allow | 36 | 6 | 0 | Yes | No |
| 17714295 | EXOSOME-BASED CANCER ASSAYS | April 2022 | December 2023 | Allow | 20 | 4 | 1 | Yes | No |
| 17679213 | Low dose antibody-based methods for treating hematologic malignancies | February 2022 | May 2025 | Allow | 39 | 1 | 0 | No | No |
| 17631200 | SOLUBLE PROGRAMMED CELL DEATH PROTEIN-1 AS A BIOMARKER IN CANCER PATIENTS | January 2022 | August 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17560006 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | December 2021 | June 2022 | Allow | 6 | 1 | 0 | No | No |
| 17558404 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA | December 2021 | June 2022 | Allow | 6 | 1 | 0 | No | No |
| 17552137 | METHODS FOR IDENTIFYING BETA-GLUCAN BINDING TO IMMUNE CELLS | December 2021 | April 2025 | Allow | 40 | 2 | 1 | No | No |
| 17519183 | Anti-CD25 Antibody-Maytansine Conjugates and Methods of Use Thereof | November 2021 | August 2023 | Allow | 21 | 2 | 0 | Yes | No |
| 17599309 | FUNCTIONALIZED POLY-ADP-RIBOSE POLYMERS FOR DRUG DELIVERY | September 2021 | September 2022 | Allow | 11 | 2 | 0 | No | No |
| 17483588 | MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | September 2021 | January 2025 | Allow | 40 | 1 | 0 | No | No |
| 17476683 | Humanised Anti Kallikrein-2 Antibody | September 2021 | April 2025 | Allow | 43 | 2 | 0 | No | No |
| 17439498 | Immunoconjugates Targeting CEA | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17437617 | Immunoconjugates Targeting PD-L1 | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17434112 | COMPOUNDS USEFUL AS ADJUVANTS | August 2021 | June 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17372354 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE | July 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17351341 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17345457 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | June 2021 | July 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17339157 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | June 2021 | April 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17333945 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | May 2021 | April 2024 | Allow | 35 | 1 | 0 | No | No |
| 17334073 | CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER | May 2021 | June 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17308570 | Cancer Drug and Uses | May 2021 | June 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17241654 | METHODS FOR TREATING FIBROTIC CANCERS | April 2021 | June 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17283903 | DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF | April 2021 | March 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17224722 | Methods for Manipulating Phagocytosis Mediated by CD47 | April 2021 | July 2024 | Allow | 40 | 2 | 0 | No | No |
| 17205251 | COMPOSITIONS AND METHODS TO ENHANCE THE IMMUNE SYSTEM | March 2021 | April 2024 | Allow | 37 | 1 | 0 | No | No |
| 17275528 | SUBSTITUTED BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | March 2021 | June 2025 | Abandon | 51 | 0 | 1 | No | No |
| 17198103 | Compositions and Methods for Selective Phagocytosis of Human Cancer Cells | March 2021 | May 2025 | Allow | 50 | 2 | 0 | No | No |
| 17195072 | METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION | March 2021 | April 2024 | Allow | 38 | 1 | 0 | No | No |
| 17190792 | PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER | March 2021 | June 2022 | Allow | 15 | 3 | 0 | Yes | No |
| 17189135 | Drug-Conjugates, Conjugation Methods, And Uses Thereof | March 2021 | June 2024 | Allow | 39 | 1 | 0 | No | No |
| 17181896 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | February 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17270034 | ANTI-PD-L1 CANCER IMMUNOTHERAPY ANTIBODIES | February 2021 | April 2025 | Allow | 50 | 3 | 0 | No | No |
| 17268387 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | February 2021 | December 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17169093 | CANCER ANTIGEN SPECIFIC CYTOTOXIC T CELL | February 2021 | January 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17163205 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | January 2021 | April 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17159798 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | January 2021 | September 2024 | Allow | 43 | 3 | 0 | No | No |
| 17153711 | NAPI2B-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | January 2021 | June 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17151898 | BI-FUNCTIONAL ALLOSTERIC PROTEIN-DRUG MOLECULES FOR TARGETED THERAPY | January 2021 | December 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17149405 | BIASED IL2 MUTEINS METHODS AND COMPOSITIONS | January 2021 | May 2022 | Allow | 16 | 3 | 0 | Yes | No |
| 17260205 | BISPECIFIC AFFINITY REAGENT AND RELATED METHODS FOR PRETARGETED RADIOIMMUNOTHERAPY AGAINST CD45+ CELLS | January 2021 | May 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17146070 | METHOD AND COMPOSITIONS FOR DETECTING AN ADENOMA-ADENOCARCINOMA TRANSITION IN CANCER | January 2021 | February 2024 | Allow | 37 | 2 | 0 | No | No |
| 17141931 | CD123 Antibodies and Conjugates Thereof | January 2021 | December 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17129633 | YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS | December 2020 | December 2023 | Allow | 36 | 2 | 0 | No | No |
| 17128944 | TUMOR LYSATE LOADED PARTICLES | December 2020 | December 2023 | Abandon | 36 | 1 | 0 | No | No |
| 17253086 | BINDER/ACTIVE AGENT CONJUGATES DIRECTED AGAINST CXCR5, HAVING ENZYMATICALLY CLEAVABLE LINKERS AND IMPROVED ACTIVITY PROFILE | December 2020 | April 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17251657 | CONJUGATE | December 2020 | June 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17111982 | SELF-STABILIZING LINKER CONJUGATES | December 2020 | October 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17058190 | STABLE FUSION PROTEIN FORMULATION | November 2020 | June 2025 | Allow | 54 | 3 | 0 | No | No |
| 17057589 | PHTHALOCYANINE DYE CONJUGATE COMPOSITIONS | November 2020 | April 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 16951722 | NEO-EPITOPE VACCINES AND METHODS OF TREATING CANCER | November 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17088220 | TREATMENT OF OVARIAN CANCER IN PATIENTS WITH ASCITES USING A SPECIFIC BINDING AGENT OF HUMAN ANGIOPOIETIN-2 IN COMBINATION WITH A TAXANE | November 2020 | August 2023 | Allow | 34 | 1 | 0 | No | No |
| 17077661 | AUTOIMMUNE ANTIGENS AND CANCER | October 2020 | October 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17076677 | IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT | October 2020 | September 2021 | Allow | 10 | 1 | 0 | No | No |
| 17046694 | COMPOSITIONS AND METHODS FOR TREATING NECROTIZING ENTEROCOLITIS | October 2020 | March 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17045380 | ANTIBODY FORMULATION | October 2020 | March 2024 | Allow | 41 | 1 | 0 | No | No |
| 17032219 | CAMPTOTHECIN DERIVATIVES | September 2020 | September 2021 | Allow | 12 | 1 | 1 | No | No |
| 17022560 | Patient Treatment Via Teratogenic Pharmaceutical Compounds | September 2020 | February 2024 | Allow | 41 | 2 | 0 | No | No |
| 17015290 | ANTI-HIV ANTIBODIES | September 2020 | January 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17006681 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | August 2020 | October 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16975406 | NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE | August 2020 | November 2024 | Allow | 51 | 2 | 0 | Yes | No |
| 16992232 | METHODS FOR DETECTION OF CIRCULATING TUMOR CELLS AND METHODS OF DIAGNOSIS OF CANCER IN A MAMMALIAN SUBJECT | August 2020 | October 2023 | Abandon | 38 | 1 | 0 | No | No |
| 16989654 | FUSION PROTEIN CONTAINING TRAIL AND IGG BINDING DOMAIN AND THE USES THEREOF | August 2020 | January 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 16641281 | METHODS OF INACTIVATING VIRAL CONTAMINANTS | August 2020 | November 2024 | Allow | 57 | 2 | 0 | No | No |
| 16966442 | VACCINE COMPOSITION AND USES THEREOF | July 2020 | January 2025 | Allow | 54 | 2 | 0 | No | No |
| 16933845 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | July 2020 | March 2021 | Allow | 8 | 2 | 0 | No | No |
| 16963185 | ANTI-TUMOR THERAPEUTIC AGENTS BASED ON B7H RECEPTOR LIGANDS | July 2020 | January 2025 | Allow | 54 | 3 | 0 | Yes | No |
| 16920880 | PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER | July 2020 | March 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16959867 | COMPOSITIONS AND METHODS FOR INHIBITION OF ALPHAVIRUS INFECTION | July 2020 | March 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 16959950 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | July 2020 | February 2024 | Abandon | 43 | 2 | 0 | No | No |
| 16919191 | Radiohalogenated Agents for in Situ Immune Modulated Cancer Vaccination | July 2020 | June 2024 | Allow | 47 | 2 | 0 | No | No |
| 16918520 | MEDICINE FOR TREATING CANCER AND METHOD FOR TREATING CANCER | July 2020 | July 2023 | Allow | 36 | 1 | 0 | No | No |
| 16918527 | COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER | July 2020 | September 2024 | Allow | 51 | 3 | 0 | No | No |
| 16959644 | NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE | July 2020 | December 2023 | Allow | 42 | 1 | 0 | Yes | No |
| 16959288 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | June 2020 | October 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16959425 | NOVEL COMBINATION AND USE OF ANTIBODIES | June 2020 | February 2025 | Allow | 56 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CANELLA, KAREN A.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CANELLA, KAREN A works in Art Unit 1643 and has examined 1,245 patent applications in our dataset. With an allowance rate of 59.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner CANELLA, KAREN A's allowance rate of 59.9% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CANELLA, KAREN A receive 2.40 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CANELLA, KAREN A is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +34.7% benefit to allowance rate for applications examined by CANELLA, KAREN A. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.7% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 55.7% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 89.9% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 90.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 60.3% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.2% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 46% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.